

# Anti-CD6 (Itolizumab), Humanized Antibody

07/20

---

**CATALOG NO.:** A2164-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a humanized recombinant IgG1 monoclonal antibody that specifically targets the scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. CD6 is a co-stimulatory molecule that is primarily expressed on the T-cell surface and plays an important role in the maturation, activation, and differentiation of T-cells, and pro-inflammatory cytokine production. Binding of the antibody to CD6 prevents T-cell activation, decreases the levels of IFN- $\gamma$ , IL-6, and TNF- $\alpha$  and thus reduces inflammation. The original drug was approved by the DCGI in India to treat moderate-to-severe plaque psoriasis. In 2020, the drug received approval to treat moderate-to-severe COVID-19 complications.

**ALTERNATE NAMES:** T1h, XQQ2RHV14N, TP120, T12

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** 1 mg/ml

**HOST/ISOTYPE:** Recombinant / IgG1, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human CD6

**CAS NUMBER:** 1116433-11-4

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-IL-17 $\alpha$  (Ixekizumab), Humanized Antibody (A2149)  
 Anti-IL-6R $\alpha$  (Sarilumab), Human IgG1 Antibody (A2133)  
 Anti-IL-17 $\alpha$  (Secukinumab), Human IgG1 Antibody (A2154)  
 Anti-IL-17R $\alpha$  (Brodalumab), Human IgG2 Antibody (A2155)  
 Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)  
 Anti-IL-1 $\beta$  (Canakinumab), Human IgG1 Antibody (A2144)

**FOR RESEARCH USE ONLY! Not to be used on humans.**